Composition for improving hyperuricemia or regulating uric acid balance and application thereof

Abstract

The invention discloses a composition for improving hyperuricemia or regulating uric acid balance and application thereof, the composition comprises the following components: a passion fruit extract, a sophora flower bud extract and a green coffee extract, and the weight part ratio of the passion fruit extract to the sophora flower bud extract to the green coffee extract is (14-129): (7-70): (14-84). According to the composition for improving hyperuricemia or regulating uric acid balance, the passion fruit extract, the sophora flower bud extract and the green coffee extract are combined for use, the composition is prepared from natural products, scientific verification shows that the composition is reasonable in proportion, has obvious synergistic interaction, has a uric acid reducing function, can be applied to tablets, powder, hard capsules, soft capsules and soft sweets, and has a good application prospect. Granular preparations or oral liquid and the like.

Description

Technical Field

[0001] The present invention relates to the technical field of food or health food and pharmaceutical compositions, and in particular to a composition for improving hyperuricemia or regulating uric acid balance and an application thereof. Background Art

[0002] Uric acid is a trioxypurine, and its alcohol form is weakly acidic. It is mainly produced by the liver metabolism of purine compounds ingested by diet and decomposed in the body. Uric acid is produced by the enzymatic reaction of xanthine and hypoxanthine decomposed by purine in the body through xanthine oxidase (XOD), and is excreted through the kidneys and digestive tract. Hyperuricemia (HUA) is a common metabolic disease induced by reduced excretion or increased synthesis of uric acid in the body. Its long-term harm includes not only gout, hypertension, uric acid nephropathy and hyperlipidemia, but also serious cardiovascular diseases such as coronary heart disease, which seriously endangers human health.

[0003] In recent years, with the development of my country's economy and society and the changes in dietary structure and lifestyle, hyperuricemia in my country is currently increasing year by year, and is showing a trend of younger onset, especially in coastal areas. The current clinical treatment of hyperuricemia mainly uses XOD inhibitors, such as allopurinol and febuxostat, and uricosuric drugs such as benzbromarone, but these drugs have defects such as few varieties, more serious side effects, and strong drug resistance. The side effects include kidney burden and damage, liver damage, diarrhea, etc. Therefore, it is of great significance to study effective methods to prevent and treat hyperuricemia.

[0004] In addition to the above clinical drugs, Chinese medicine compositions and Chinese patent medicines have also been commonly used in recent years to relieve the symptoms of hyperuricemia, such as Dixiefenqing Pills, Bazheng Tablets, Simiao Pills, etc., whose main functions are to clear away heat and dampness, and to promote blood circulation and remove blood stasis. However, there are some shortcomings in current Chinese patent medicines. Their efficacy and indications are single, and they mainly treat joint redness and swelling, muscle and bone pain caused by gout. Secondly, after long-term use of Chinese patent medicines, patients will experience many uncomfortable symptoms such as spleen deficiency, coldness, kidney and gastrointestinal burden, etc. In addition, the current Chinese patent medicine formulas on the market are complex, which makes quality control difficult and may introduce raw materials that are harmful to the human body. Summary of the invention

[0005] In view of the deficiencies in the prior art, the present invention provides a composition for improving hyperuricemia or regulating uric acid balance and its application, which is made from natural products, has the function of lowering uric acid, and can be applied to tablets, powders, hard capsules, soft capsules, soft candies, granular preparations or oral liquids, etc.

[0006] The present invention is achieved through the following technical solutions:

[0007] A composition for improving hyperuricemia or regulating uric acid balance, comprising components: passion fruit extract and sophora japonica extract, wherein the weight ratio of the passion fruit extract to the sophora japonica extract is (14-129):(7-70).

[0008] Furthermore, in parts by weight, the weight ratio of the passion fruit extract to the sophora japonica flower extract is (28-98):(14-70).

[0009] Furthermore, it also includes a component: green coffee extract. In terms of weight, the weight ratio of the passion fruit extract, the sophora japonica seed extract and the green coffee extract is (14-129):(7-70):(14-84).

[0010] Furthermore, in terms of weight, the weight ratio of the passion fruit extract, the sophora japonica extract, and the green coffee extract is (28-98):(14-70):(14-30).

[0011] The present invention also provides the use of any of the above-mentioned compositions for improving hyperuricemia or regulating uric acid balance in the preparation of a product having the function of regulating uric acid metabolism.

[0012] The present invention also provides a product having the function of improving hyperuricemia or regulating uric acid balance, which comprises any of the above-mentioned compositions for improving hyperuricemia or regulating uric acid balance.

[0013] Furthermore, the product dosage forms include tablets, powders, hard capsules, soft capsules, soft candies, granular preparations, and oral liquids.

[0014] Furthermore, the product is a tablet, comprising the following components by weight: 14 parts of passion fruit extract, 70 parts of sophora japonica extract, 56 parts of green coffee extract, 128 parts of microcrystalline cellulose, and 3 parts of magnesium stearate.

[0015] Furthermore, the product is a chewable tablet, comprising the following components by weight: 66 parts of passion fruit extract, 56 parts of sophora japonica extract, 84 parts of green coffee extract, 188 parts of sorbitol, 32 parts of citric acid, 3 parts of coffee essence, 39 parts of arabinose, and 3 parts of magnesium stearate.

[0016] Furthermore, the product is a direct drinking powder, which includes the following components by weight: 129 parts of passion fruit extract, 7 parts of Sophora japonica extract, 14 parts of green coffee extract, 37.5 parts of resistant dextrin, 435 parts of erythritol, 82.5 parts of cranberry juice powder, and 45 parts of citric acid.

[0017] Compared with the prior art, the advantages of the present invention are:

[0018] 1. The present invention first discovered that picotrin, especially passion fruit extract, with a content of ≥3.5%, has uric acid lowering activity or improves hyperuricemia, mainly by inhibiting the activity of xanthine oxidase in vitro and increasing the expression of the hprt1 hypoxanthine transferase 1 gene in zebrafish. The enzyme is a key enzyme in the purine metabolic salvage pathway, affects purine metabolism, and indirectly reduces uric acid production. In addition, picotrin can increase the expression of the oat1 uric acid excretion gene, thereby showing a decrease in uric acid fluorescence value.

[0019] 2. The present invention discovers for the first time that the combined use of passion fruit extract, sophora japonica extract and green coffee extract has a synergistic effect of lowering uric acid, can inhibit XOD activity, and can significantly reduce the uric acid fluorescence value in zebrafish tissues in a hyperuricemia zebrafish model. This is mainly achieved by increasing the expression of the oat1 uric acid excretion gene and the hprt1 hypoxanthine transferase 1 gene in zebrafish, promoting uric acid excretion and reducing uric acid formation, thereby reducing uric acid content. The effect is significantly better than that of a single prescription, showing a dose-effect relationship.

[0020] 3. Compared with a single raw material, the composition of the present invention can significantly reduce the uric acid fluorescence value of zebrafish tissue after taking it for a shorter period of time.

[0021] 4. The composition of the present invention has simple ingredients, clear proportions, and sufficient evidence. It regulates the balance of uric acid in the body through multiple pathways, such as inhibiting the activity of xanthine oxidase (XOD), increasing the expression of the hprt1 hypoxanthine transferase 1 gene, reducing the synthesis of uric acid from the source, and increasing uric acid excretion and transport, and has a protective effect on the kidneys.

[0022] 5. All kinds of raw materials of the present invention are derived from raw materials that are both medicinal and edible and can be used as natural health products, with no side effects and good safety. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 :Changes in uric acid fluorescence values ​​of each experimental group in zebrafish uric acid experiment;

[0024] Figure 2 :Changes in uric acid fluorescence values ​​during different experimental periods in zebrafish uric acid experiments;

[0025] Figure 3 : Changes in the expression of oat1 gene in each experimental group of zebrafish uric acid experiment;

[0026] Figure 4 : Changes in hprt1 gene expression in each experimental group of zebrafish uric acid efficacy experiment. DETAILED DESCRIPTION

[0027] The present invention provides a composition for improving hyperuricemia or regulating uric acid balance, comprising components: passion fruit extract and sophora japonica extract. In terms of weight, the weight ratio of passion fruit extract to sophora japonica extract is (14-129): (7-70), and more preferably, (28-98): (14-70).

[0028] Among them, the main active ingredient of passion fruit extract is piceatannol, and other extracts containing piceatannol can also be used as a substitute. The extracts containing piceatannol include but are not limited to those extracted from the following raw materials: passion fruit and seeds, twigs or bark of piceatannol, blueberry extract, grape extract, passion fruit, and Alsophila spinulosa of the genus Alsophila of the family Alsophila.

[0029] Optionally, the composition further comprises a component: green coffee extract. In terms of weight, the weight ratio of passion fruit extract, sophora japonica extract and green coffee extract is (14-129):(7-70):(14-84), preferably (28-98):(14-70):(14-30), and more preferably 66:56:18.

[0030] The present invention also provides an application of a composition for improving hyperuricemia or regulating uric acid balance in preparing a product having the function of regulating uric acid metabolism, and a product having the function of improving hyperuricemia or regulating uric acid balance. Specifically, the product can be a tablet, powder, hard capsule, soft capsule, soft candy, granule preparation, oral liquid, etc.

[0031] Optionally, the product is a tablet, comprising the following components by weight: 14 parts of passion fruit extract, 70 parts of sophora japonica extract, 56 parts of green coffee extract, 128 parts of microcrystalline cellulose, and 3 parts of magnesium stearate.

[0032] Optionally, the product is a chewable tablet, comprising the following components by weight: 66 parts of passion fruit extract, 56 parts of Sophora japonica extract, 84 parts of green coffee extract, 188 parts of sorbitol, 32 parts of citric acid, 3 parts of coffee essence, 39 parts of arabinose, and 3 parts of magnesium stearate.

[0033] Optionally, the product is a direct drinking powder, comprising the following components by weight: 129 parts of passion fruit extract, 7 parts of Sophora japonica extract, 14 parts of green coffee extract, 37.5 parts of resistant dextrin, 435 parts of erythritol, 82.5 parts of cranberry juice powder, and 45 parts of citric acid.

[0034] For ease of understanding, the following specific embodiments are provided:

[0035] Example 1: In vitro screening of xanthine oxidase activity

[0036] 1. Experimental Materials and Instruments

[0037] 1.1 Samples and reagents: passion fruit extract, sophora japonica extract, green coffee extract, grape extract, xanthine, xanthine oxidase (XOD), allopurinol, sodium hydroxide, 37% hydrochloric acid, NaH2PO4·2H2O; Na2HPO4·12H2O.

[0038] 1.2 Instruments: ultrasonic cleaning machine, UV-VIS spectrophotometer, electric constant temperature water bath, analytical balance, vortex oscillator, dryer.

[0039] 2. Test methods

[0040] 2.1 Configuration of main reagents

[0041] Preparation of phosphate buffer: prepare 0.2mol / L phosphate buffer with pH=7.5. Preparation of xanthine solution: weigh 15mg xanthine and add 250mL 0.05mol / L phosphate buffer to a volumetric flask, ultrasonically dissolve for 10min to obtain 0.4mmol / L xanthine solution, and dilute with 0.05mol / L phosphate buffer to obtain 0.2mmol / L xanthine solution. Preparation of xanthine oxidase solution: take 8.4U / ml xanthine oxidase solution, add PBS solution to obtain 0.05U / mL enzyme solution.

[0042] 2.2 Determination of the inhibition rate of samples on xanthine oxidase

[0043] With xanthine as substrate, xanthine oxidase combines with xanthine to generate uric acid. Based on the principle that the sample and xanthine substrate competitively bind to the xanthine oxidase site, the xanthine oxidase inhibition rate of each sample is calculated by measuring the uric acid characteristic absorption peak at 290nm to reflect the amount of uric acid generated. The amount of each solution added in the experimental system is shown in Table 1.

[0044] Table 1 In vitro xanthine oxidase activity determination solution addition amount

[0045]

[0046] Add phosphate buffer, test solution and xanthine oxidase solution in a 10mL brown centrifuge tube, preheat in a 37℃ water bath for 15min, then add xanthine solution in turn, shake evenly, continue to react in a 37℃ water bath for 30min, then add hydrochloric acid solution in turn to terminate the system reaction, and measure the absorbance value of each group at 290nm. Calculate the xanthine oxidase inhibition rate of each group of samples according to the following formula.

[0047]

[0048] Apx: absorbance value of the sample group to be tested; Ac: absorbance value of the control group; A0 : Absorbance value of blank group.

[0049] Table 2 Sample group types and proportion information

[0050]

[0051]

[0052] Experimental Results

[0053] From the results of the xanthine oxidase inhibition activity of the samples in Table 3, it can be seen that the green coffee extract alone has a very weak inhibitory effect on XOD, and the inhibition rates of passion fruit extract and Sophora japonica extract alone are both ≤50%. From the results of samples 4-6, it can be seen that when green coffee extract is used in combination with passion fruit extract and Sophora japonica extract, the inhibition rate of XOD is higher than the inhibition rate of each single side, proving that there is an obvious synergistic effect between passion fruit extract, Sophora japonica extract and green coffee extract.

[0054] Among the three samples 7-13, the inhibition rates of samples 8-13 are better than those of sample 7, and higher than those of the corresponding two-way compatibility (samples 4-6) and single-way (samples 1-3). Sample 9 has the best inhibition effect, and the inhibition rates of samples 7 and 11 are lower than those of the other three-way compatibility, indicating that the combined use of passion fruit extract, Sophora japonica extract, and green coffee extract within an appropriate ratio can significantly enhance the inhibitory effect of the composition on XOD. When grape extract is used to replace passion fruit extract in the same proportion, the inhibition rate results are similar, proving that the piceatannol contained therein is the main active substance with uric acid-lowering effect and synergistic effect.

[0055] Table 3 Results of xanthine oxidase inhibition rate of sample groups

[0056]

[0057]

[0058] Example 2: Functional activity test of samples on hyperuricemia zebrafish model

[0059] 1. Experimental Methods

[0060] 1.1 Experimental animals: Wild-type zebrafish AB strain, incubated in a 28°C incubator

[0061] 1.2 Experimental model: zebrafish were treated with potassium oxonate and sodium xanthine to establish a zebrafish hyperuricemia model

[0062] 1.3 Experimental groups: There were 9 experimental groups in total, including 1 normal group, 1 model control group, 1 positive control group (allopurinol), and 6 sample groups. Each experimental group consisted of 30 zebrafish.

[0063] 1.4 Detection method: After the sample treatment, the zebrafish samples were processed according to the instructions of the uric acid kit, and the data were collected using a multifunctional microplate reader to analyze the zebrafish uric acid fluorescence value. This indicator was used to evaluate whether the compound and single prescriptions were effective, and the differences between single prescriptions and compound prescriptions and between compound prescriptions were compared. The statistical processing results were expressed as mean ± SD. SPSS IBM software was used for statistical analysis, and P < 0.05 indicated a statistically significant difference.

[0064] 2. Experimental results

[0065] 2.1 Changes in uric acid fluorescence levels

[0066] Depend on Figure 1 It can be seen that on the 2nd day of the experiment, compared with the normal group, the uric acid fluorescence value of zebrafish in the model control group was significantly increased (P<0.001), proving that the zebrafish hyperuricemia model was successfully established; compared with the model control group, the uric acid fluorescence value level of zebrafish in the positive drug allopurinol group was significantly reduced (P<0.001), with a decrease of about 57%; the uric acid fluorescence value of zebrafish in sample 1, 2, 8, 9, 10, and 12 groups was significantly reduced (P<0.001); proving that samples 1, 2, 8, 9, 10, and 12 all have significant uric acid-lowering effects.

[0067] The uric acid fluorescence values ​​of samples 8, 9, 10, and 12 were significantly lower than those of samples 1 and 2, while samples 9 and 10 had the best effects and were significantly better than samples 1 and 2 (P<0.001); it proved that the combined use of the three raw materials can significantly enhance the uric acid lowering effect; there was no significant difference between the uric acid fluorescence values ​​of samples 9 and 10 and the positive drug group (allopurinol) (P>0.05), and the uric acid lowering effect was equivalent to the positive drug allopurinol. Therefore, it was proved that within a certain dosage range, the uric acid fluorescence value can be minimized by increasing the proportion of passion fruit extract and combining it with Sophora japonica extract and green coffee extract, that is, the uric acid lowering effect can reach the highest level.

[0068] Depend on Figure 2It can be seen that when the zebrafish drug administration experiment was t days, the uric acid fluorescence values ​​of samples 8-12 were significantly lower than those of the model control group, and there was an obvious effect at a lower concentration; while for samples 1 and 2, even if the concentration was increased to 4 times the lowest concentration of samples 8-12, although uric acid showed a decreasing trend, there was still no statistical difference with the model group (p>0.05); by extending the drug administration period to 2t, the uric acid fluorescence values ​​of each experimental group showed a significant decrease, and samples 8-12 showed a dose-effect relationship (data not shown), and were effective at low concentrations, while samples 1 and 2 showed a significant decrease at medium concentrations. The legend shows that at the same concentration, samples 8-12 were better than samples 1-2, and samples 9 and 10 were the best, indicating that compared with passion fruit extract and Sophora japonica extract alone, the combined use of passion fruit extract and green coffee extract has a shorter synergistic uric acid-lowering effect time, a lower dosage, and more obvious synergy.

[0069] 2.2 Changes in zebrafish uric acid-related genes:

[0070] like Figure 3 , 4 The results of gene testing showed that samples 1, 2, 8, 9, 10, and 12 could increase the expression of oat1 uric acid excretion gene and hprt1 hypoxanthine phosphoribosyltransferase 1 gene, which were significantly higher than those in the model control group (P<0.001). Among them, the effects of samples 8, 9, 10, and 12 were significantly better than those of single prescriptions (sample 1 and sample 2) (P<0.05), and samples 9 and 10 were the best. This proved that the combined use of the three raw materials can significantly increase the uric acid-lowering efficacy by promoting the expression of oat1 and hprt1 genes, and a dose-multiple relationship was found (not shown in this article).

[0071] The hprt1 and oat1 genes in sample groups 9 and 10 showed the highest increase, proving that when the three ingredients were used in combination, the uric acid fluorescence value in the sample group with a higher proportion of passion fruit extract would be lower, which may be due to the mechanism of regulating the expression of uric acid synthesis and excretion genes.

[0072] Example 3: Preparation of a tablet product with the function of regulating uric acid metabolism

[0073] A raw material formula for a product tablet with a function of regulating uric acid, comprising the following components by weight: 14 parts of passion fruit extract, 70 parts of sophora japonica seed extract, 56 parts of green coffee extract, 128 parts of microcrystalline cellulose, and 3 parts of magnesium stearate.

[0074] A method for preparing a product tablet having a uric acid-lowering function, comprising the following steps:

[0075] (1) Dry premix: Mix the passion fruit extract, sophora japonica extract and green coffee extract in the formula amount and put them into a mixing tank to obtain a dry premix.

[0076] (2) Mixing: The dry premix and microcrystalline cellulose in the formula amount are put into a mixing tank for mixing. After mixing for 20 to 30 minutes, magnesium stearate is added and mixed for 2 to 3 minutes. The total mixture is discharged.

[0077] (3) Tablet preparation: The total mixture is put into a tablet press for tableting, 0.5 g / tablet, and the tablet weight difference, hardness and friability are measured, and the tablets are discharged.

[0078] (4) Packaging: Packed in HDPE bottles with built-in desiccant.

[0079] Example 4: Preparation of a chewable tablet having the function of regulating uric acid metabolism

[0080] A raw material formula for a chewable tablet with a uric acid regulating function comprises the following components by weight: 66 parts of passion fruit extract, 56 parts of sophora japonica extract, 84 parts of green coffee extract, 188 parts of sorbitol, 32 parts of citric acid, 3 parts of coffee essence, 39 parts of arabinose, and 3 parts of magnesium stearate.

[0081] A method for preparing a chewable tablet having a uric acid regulating function comprises the following steps:

[0082] (1) Drying the premix: Mix the formulated amount of citric acid and sorbitol, put them into a vacuum drying oven for reduced pressure drying, control the vacuum at -0.08 to 0.1 MPa, control the jacket water temperature at 60 to 65°C, and keep warm for 2.0 hours. During this period, take samples to measure the water activity of the premix. If the water activity is greater than 0.12, continue to keep warm until the water activity is ≤0.12, stop keeping warm, reduce the material temperature to ≤28°C, and then discharge the material to obtain a dry premix.

[0083] (2) Mixing: Weigh the formula amount of passion fruit extract, Sophora japonica extract, green coffee extract, coffee essence, arabinose and the dry premix obtained in step 1, put them into a mixing tank, mix for 30 minutes, add magnesium stearate, mix for 2-3 minutes, and discharge.

[0084] (3) Tabletting: Tablets are pressed using a tablet press, 1.4 g / tablet, and the tablet weight difference, hardness, and friability are measured before tableting.

[0085] (4) Packaging: Packed in HDPE bottles with built-in desiccant.

[0086] Experimental Example 5: Preparation of a direct drinking powder for a product that regulates uric acid metabolism

[0087] A formula of raw and auxiliary materials for a direct drinking powder with a function of regulating uric acid (by weight): 129 parts of passion fruit extract, 7 parts of sophora japonica extract, 14 parts of green coffee extract, 37.5 parts of resistant dextrin, 435 parts of erythritol, 82.5 parts of cranberry juice powder, and 45 parts of citric acid.

[0088] A method for preparing a direct drinking powder having a uric acid regulating function comprises the following steps:

[0089] (1) Dry premix: According to the formula ratio, 129 parts of passion fruit extract, 7 parts of Sophora japonica extract, 14 parts of green coffee extract, 37.5 parts of resistant dextrin, and 45 parts of citric acid were weighed and mixed to obtain a dry premix.

[0090] (2) Mixing: Weigh 435 parts of erythritol and 82.5 parts of cranberry juice powder, put them into a mixing tank, mix them, add the dry premix in step 1, pass through a 40-mesh sieve to prevent lumps, and mix them evenly.

[0091] (3) Filling: Pack the material obtained in step 2, 0.8 g / piece, to obtain the finished product, once a day.

[0092] The above embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the present invention. It should be pointed out that, for a person of ordinary skill in the art, several modifications and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the present invention patent shall be subject to the attached claims.

Claims

1. A composition for improving hyperuricemia or regulating uric acid balance, characterized in that: The invention comprises the following components: passion fruit extract and sophora japonica extract. The weight ratio of the passion fruit extract to the sophora japonica extract is (14-129):(7-70).

2. The composition for improving hyperuricemia or regulating uric acid balance according to claim 1, characterized in that: In terms of weight, the weight ratio of the passion fruit extract to the sophora japonica flower extract is (28-98):(14-70).

3. The composition for improving hyperuricemia or regulating uric acid balance according to claim 1, characterized in that: It also includes a component: green coffee extract. By weight, the weight ratio of the passion fruit extract, the sophora japonica seed extract and the green coffee extract is (14-129):(7-70):(14-84).

4. The composition for improving hyperuricemia or regulating uric acid balance according to claim 3, characterized in that: In terms of weight, the weight ratio of the passion fruit extract, the sophora japonica extract and the green coffee extract is (28-98):(14-70):(14-30).

5. Use of the composition for improving hyperuricemia or regulating uric acid balance according to any one of claims 1 to 4 in the preparation of a product having the function of regulating uric acid metabolism.

6. A product having the function of improving hyperuricemia or regulating uric acid balance, characterized in that: A composition for improving hyperuricemia or regulating uric acid balance comprising the composition according to any one of claims 1 to 4.

7. The product having the function of improving hyperuricemia or regulating uric acid balance according to claim 6, characterized in that: The product dosage forms include tablets, powders, hard capsules, soft capsules, soft candies, granule preparations, and oral liquids.

8. The product having the function of improving hyperuricemia or regulating uric acid balance according to claim 7, characterized in that: The product is a tablet, and comprises the following components by weight: 14 parts of passion fruit extract, 70 parts of sophora japonica extract, 56 parts of green coffee extract, 128 parts of microcrystalline cellulose, and 3 parts of magnesium stearate.

9. The product having the function of improving hyperuricemia or regulating uric acid balance according to claim 7, characterized in that: The product is a chewable tablet, which comprises the following components by weight: 66 parts of passion fruit extract, 56 parts of sophora japonica extract, 84 parts of green coffee extract, 188 parts of sorbitol, 32 parts of citric acid, 3 parts of coffee essence, 39 parts of arabinose, and 3 parts of magnesium stearate.

10. The product having the function of improving hyperuricemia or regulating uric acid balance according to claim 7, characterized in that: The product is a direct drinking powder, and comprises the following components by weight: 129 parts of passion fruit extract, 7 parts of Sophora japonica extract, 14 parts of green coffee extract, 37.5 parts of resistant dextrin, 435 parts of erythritol, 82.5 parts of cranberry juice powder, and 45 parts of citric acid.

Images